Eosinophilic Asthma Clinical Trial
Official title:
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.
Demonstrate the efficacy of reslizumab, at a dose of 3 mg/kg administered iv every 4 weeks over 12 months, as assessed by the reduction in frequency of clinical asthma exacerbations (CAEs) during 12 months. An exacerbation event will be considered a CAE if the patient meets either or both of the criteria listed below and this is corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma: - use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days - asthma-related emergency treatment The above criteria must be corroborated with at least 1 other measurement to indicate worsening in the clinical signs and symptoms of asthma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05398133 -
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
|
||
| Recruiting |
NCT04585997 -
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
|
Phase 4 | |
| Recruiting |
NCT05985694 -
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
|
Phase 2 | |
| Completed |
NCT03563521 -
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
|
||
| Completed |
NCT03469934 -
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
|
Phase 2 | |
| Enrolling by invitation |
NCT06388889 -
Phase III Long-Term Extension Study With Dexpramipexole
|
Phase 3 | |
| Recruiting |
NCT04187976 -
Eosinophils Endotypes in Chronic Airway Inflammatory Diseases
|
||
| Recruiting |
NCT05813288 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
|
Phase 3 | |
| Completed |
NCT01285323 -
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
|
Phase 3 | |
| Completed |
NCT03696914 -
Intense Airway Eosinophilia in Asthma
|
||
| Terminated |
NCT01290887 -
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
|
Phase 3 | |
| Recruiting |
NCT04228588 -
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
|
Phase 4 | |
| Recruiting |
NCT05748600 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
|
Phase 3 | |
| Recruiting |
NCT05763121 -
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
|
Phase 3 | |
| Completed |
NCT01508936 -
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
|
Phase 3 | |
| Recruiting |
NCT04538937 -
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
|
||
| Completed |
NCT05002621 -
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
|
||
| Completed |
NCT01270464 -
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
|
Phase 3 | |
| Completed |
NCT04674137 -
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
|
Phase 2 | |
| Recruiting |
NCT04671446 -
Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma
|